Literature DB >> 23421587

Prognostic factors for visual recovery after transsphenoidal pituitary adenectomy.

Sangmoon Lee1, Seong-Joon Kim, Young Suk Yu, Yong Hwy Kim, Sun Ha Paek, Dong Gyu Kim, Hee-Won Jung.   

Abstract

OBJECTIVES: Pituitary adenomas often cause deficits in visual acuity (VA) and visual field (VF) due to compression of the optic chiasm. This study is to identify factors most likely to predict the prognosis of VA and VF after transsphenoidal pituitary adenectomy.
MATERIALS AND METHODS: Clinical records of patients who underwent transsphenoidal pituitary adenectomy were retrospectively reviewed. Data analysed included systemic and visual symptom duration, tumour size, presence of suprasellar tumour extension, histological classification of tumour, VA, and VF. VFs were determined using the Goldmann VF test and quantified according to methods outlined by the American Medical Association.
RESULTS: One-hundred and seventy eyes from 85 patients were included. Systemic and visual symptom duration, pre- and postoperative tumour size, and age did not correlate with postoperative VA or VF score. Patients with normal preoperative VA had a better postoperative VA than that of patients with preoperative VA of 20/30 or worse. Patients with normal preoperative VA had better postoperative VF score than that of patients with preoperative VA of 20/70 or worse. Postoperative VF score was lower in the preoperative ≥ 2 quadrant field loss group than in the ≤ 1 quadrant field loss group. Postoperative VA was worse in the ≥ 2 quadrant loss group than in the normal field group. Preoperative VA correlated with postoperative VA and VF score, and preoperative VF score correlated with postoperative VF score but not with VA.
CONCLUSIONS: Preoperative VA is a prognostic factor for postoperative VA and VF. Preoperative VF is predictive of postoperative VF and postoperative VA in cases with severe VF loss.

Entities:  

Mesh:

Year:  2013        PMID: 23421587     DOI: 10.3109/02688697.2013.767316

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  7 in total

1.  Predictive factors of visual function recovery after pituitary adenoma resection: a literature review and Meta-analysis.

Authors:  Min Sun; Zhi-Qiang Zhang; Chi-Yuan Ma; Sui-Hua Chen; Xin-Jian Chen
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

2.  Visual Outcomes after Endoscopic Pituitary Surgery in Patients Presenting with Preoperative Visual Deficits.

Authors:  Felipe Fredes; Gabriel Undurraga; Pablo Rojas; Felipe Constanzo; Carolina Lazcano; Jaime Pinto; Thomas Schmidt
Journal:  J Neurol Surg B Skull Base       Date:  2017-07-19

3.  Resolution of Visual Field Defect in Macroprolactinoma After Treatment With Cabergoline.

Authors:  Kimitaka Shibue; Momoko Yamakawa; Namiko Nishida; Akihiro Hamasaki
Journal:  Cureus       Date:  2022-05-31

4.  Machine Learning Prediction of Visual Outcome after Surgical Decompression of Sellar Region Tumors.

Authors:  Nidan Qiao; Yichen Ma; Xiaochen Chen; Zhao Ye; Hongying Ye; Zhaoyun Zhang; Yongfei Wang; Zhaozeng Lu; Zhiliang Wang; Yiqin Xiao; Yao Zhao
Journal:  J Pers Med       Date:  2022-01-25

5.  Parafoveal and Peripapillary Perfusion Predict Visual Field Recovery in Chiasmal Compression due to Pituitary Tumors.

Authors:  Ga-In Lee; Kyung-Ah Park; Sei Yeul Oh; Doo-Sik Kong
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

6.  Early vascular modifications after endoscopic endonasal pituitary surgery: The role of OCT-angiography.

Authors:  Gilda Cennamo; Domenico Solari; Daniela Montorio; Maria Rosaria Scala; Antonietta Melenzane; Federica Fossataro; Teresa Somma; Fausto Tranfa; Luigi Maria Cavallo
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

7.  Visual acuity and its postoperative outcome after transsphenoidal adenoma resection.

Authors:  Vicki M Butenschoen; Nina Schwendinger; Alexander von Werder; Stefanie Bette; Maximilian Wienke; Bernhard Meyer; Jens Gempt
Journal:  Neurosurg Rev       Date:  2020-10-10       Impact factor: 3.042

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.